CN105125545A - Medicine composition containing pitavastatin calcium and preparing method thereof - Google Patents
Medicine composition containing pitavastatin calcium and preparing method thereof Download PDFInfo
- Publication number
- CN105125545A CN105125545A CN201510655979.0A CN201510655979A CN105125545A CN 105125545 A CN105125545 A CN 105125545A CN 201510655979 A CN201510655979 A CN 201510655979A CN 105125545 A CN105125545 A CN 105125545A
- Authority
- CN
- China
- Prior art keywords
- pitavastatin calcium
- solid dispersion
- calcium
- pharmaceutical composition
- pitavastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine composition containing pitavastatin calcium and a preparing method thereof, and belongs to the technical field of medicine. The pitavastatin calcium contained in the medicine composition is solid dispersion of pitavastatin calcium. The medicine composition is further prepared from, by weight, 0% to 90% of filling agents, 0% to 40% of disintegrating agents, 0% to 20% of adhesives and 0% to 10% of lubricating agents. By means of the medicine composition, the stability of the pitavastatin calcium is remarkably improved, and the dissolution rate of the pitavastatin calcium is remarkably increased. The pitavastatin calcium composition prepared with the preparing method is even in content and good in dissolution effect and stability, the preparing method is simple and practicable, and industrial application is facilitated.
Description
Technical field
The invention belongs to medical art, relate to a kind of pharmaceutical composition containing Pitavastatin Calcium and preparation method thereof.
Background technology
Pitavastatin Calcium, English pitavastatin by name, chemical name is (+)-bis-{ (3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-enanthic acid } single calcium salt, it is the novel statins antilipemic drugs of Japanese Nissan chemical industry Co., Ltd. and Kowa company Ltd's joint development, listing is got permission first in Japan in July, 2003, listing dosage form is tablet, the pitavastatin calcium tablet commodity of domestic import " power clear it " by name, indication is hypercholesterolemia, familial hypercholesterolemia.Pitavastatin Calcium belongs to third generation statins, compares with other statinses, has and can effectively reduce LDL-C, TG level, pharmacokinetic indicator " excellence ", long half time, drug interaction potentiality are low, the features such as safety is good, are called as " superstatin ".
Pitavastatin Calcium, by suppressing the HMG-CoA reductase in liver, suppresses the synthesis of cholesterol to reduce the concentration of Blood Cholesterol.HMG-CoA reductase is the rate-limiting enzyme in Biosynthesis of cholesterol process, and Pitavastatin Calcium suppresses this enzyme, can reduce hepatocyte inner cholesterol content, and cell cultured supernatant surface LDL receptors is expressed to be increased, and promotes that LDL and LDL precursor is removed from circulation; In addition, by continuing the synthesis suppressing cholesterol in liver, reducing the secretion of VLDL, the concentration of triglyceride in blood can be reduced, meanwhile, enhance the reducing effect to LDL-C concentration in blood plasma.The a large amount of clinical researches carried out abroad show that Pitavastatin Calcium is to improvement treatment hypercholesterolemiapatients patients, comprise familial hyperlipidemia patient, heterozygous Familial HypercholesterolemicPatients Patients, and be safely and effectively with the hyperlipidemia patient of noninsulindependent diabetes and the status of blood lipid of hypertriglyceridemia patient, to the patient of elderly patient and hepatic insufficiency, also there is same effect.Life-time service stable curative effect, does not have serious untoward reaction and the generation of the phenomena of mortality.
Pitavastatin Calcium is unstable when pH is low, has report to be made into the preparation that pH is 8 or higher, can obtain metastable compositions.The pH value of its aqueous solution or suspension controls as being greater than 7, being less than 8, to solve its compositions poor stability and outward appearance variation issue in time by Chinese patent 96192065.3.Chinese patent 200510110676 takes compressing dry granulation, does not add binding agent, in the hope of obtaining stable compositions.
Solid dispersion technology refers to and makes medicine be highly dispersed at solid dispersion technology in suitable carrier material with molecule, crystallite or amorphous state by certain method.With solid dispersion prepared by hydrophilic carrier, the dissolution rate of insoluble drug may be added, improve the bioavailability of medicine; Medicine, under the bag of carrier material covers effect, can be avoided contacting with the direct of air, thus the oxidation slowed down in drug manufacture, storage and hydrolysis, zest and the bad smell of medicine can also be hidden.
Present inventor has carried out long-term research to the pharmaceutical composition of Pitavastatin Calcium and production technology, result forms the solid dispersion containing Pitavastatin Calcium by solid dispersion technology, not only can improve the dissolution rate of Pitavastatin Calcium, the stability of Pitavastatin Calcium can also be improved.
Summary of the invention
The technical issues that need to address of the present invention are to provide a kind of pharmaceutical composition containing Pitavastatin Calcium and preparation method thereof, said composition good stability, and active component content is even, and dissolution rate is higher.
A kind of pharmaceutical composition containing Pitavastatin Calcium, described Pitavastatin Calcium is the solid dispersion of Pitavastatin Calcium, the following material of described pharmaceutical composition also containing following percetage by weight: filler 0-90%, disintegrating agent 0-40%, binding agent 0-20%, lubricant 0-10%.
As preferably, described filler be calcium phosphate, lactose, mannitol, microcrystalline Cellulose, starch, sorbitol one or more.Described disintegrating agent be low-substituted hydroxypropyl cellulose, polyvinylpyrrolidone, starch, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone one or more.Described lubricant be magnesium stearate, stearic acid, Pulvis Talci, silicon dioxide one or more.Described binding agent be hyprolose, hypromellose, polyvinylpyrrolidone, starch slurry, water, various concentration alcoholic solution one or more.
As preferably, by weight percentage, described pharmaceutical composition is made up of the magnesium stearate of the lactose of the solid dispersion of the Pitavastatin Calcium of 1-100%, 0-90%, the low-substituted hydroxypropyl cellulose of 0-40%, the hypromellose of 0-20% and 0-10%.
As needs, other adjuvants can also be added, as coloring agent, sweeting agent, correctives, stabilizing agent.
Pitavastatin calcium composition can according to the conventional method pharmaceutical compositions prepared oral solid formulation and adopt.
Preparation process is:
The first step adopts solvent method, fusion method or solvent-fusion method to prepare the solid dispersion of Pitavastatin Calcium;
Second step accurately takes the Liprevil calcium solid dispersion containing recipe quantity Pitavastatin Calcium, press preparation industry conventional method pharmaceutical compositions with other adjuvant in prescription, directly fill out as filled capsules, powder after wet granule compression tablet, direct powder compression, granulation and rush capsule.
Pharmaceutical composition of the present invention can configure various oral solid formulation, and such as, said composition can make tablet, capsule, granule, pill, and the film-coat of these preparations or sugar-coated preparation.
For achieving the above object, present inventor has performed a series of test, the carrier of solid dispersion selects the good material of water solublity, in selection PEG4000, PEG6000, PLURONICS F87 (F68), PVPk30, one or more are the carrier of solid dispersion, the weight of described carrier is 5 times of Pitavastatin Calcium weight, the preparation method of solid dispersion adopts solvent method, fusion method, solvent-fusion method, and solvent-fusion method is more suitable for the present invention.
Pharmaceutical composition of the present invention, wherein a Liprevil calcium solid dispersion adopts solvent method preparation, carrier (one or more in PVPk30, PEG4000, PEG6000, F68) is it is characterized in that to be added in dehydrated alcohol, be stirred to and dissolve completely, add after Pitavastatin Calcium is stirred to fully mixing, removing ethanol, dry, porphyrize, sieves, and preserves.
Pharmaceutical composition of the present invention, wherein a Liprevil calcium solid dispersion adopts fusion method preparation, it is characterized in that carrier (one or more in PEG4000, PEG6000, F68) melting completely, add after Pitavastatin Calcium is stirred to fully mixing, low-temperature setting (-20 DEG C), dry, porphyrize, sieve, preserve.
Pharmaceutical composition of the present invention, wherein a Liprevil calcium solid dispersion adopts solvent-fusion method preparation, it is characterized in that Pitavastatin Calcium dehydrated alcohol to dissolve completely, carrier (one or more in PEG4000, PEG6000, F68) melting completely, add after Pitavastatin Calcium alcoholic solution is stirred to fully mixing, removing ethanol, low-temperature setting (-20 DEG C), dry, porphyrize, sieve, preserve.
Liprevil determination of calcium content:
1, chromatographic condition: be filler with octadecylsilane chemically bonded silica; With acetonitrile-water (containing 0.1% triethylamine) (40:60) for mobile phase; Determined wavelength is 244nm.Number of theoretical plate calculates by Pitavastatin Calcium peak and is not less than 5000.
2, algoscopy: compositions of getting it filled is appropriate, accurately weighed, porphyrize, add acetonitrile-water (40:60) and dissolve and make every 1ml about containing the solution of 0.04mg, filter, precision measures subsequent filtrate 20 μ l, injection liquid chromatography, record chromatogram; Separately get Pitavastatin Calcium reference substance appropriate, be measured in the same method.By external standard method with calculated by peak area, to obtain final product.
Liprevil calcium associated matters measures:
1, chromatographic condition: be filler with octadecylsilane chemically bonded silica; With acetonitrile-water (containing 0.1% triethylamine) (40:60) for mobile phase; Determined wavelength is 244nm.Number of theoretical plate calculates by Pitavastatin Calcium peak and is not less than 5000.
2, algoscopy: compositions of getting it filled is appropriate, adds acetonitrile-water (40:60) and makes the solution containing 0.2mg in every 1ml, filter, get subsequent filtrate as need testing solution; It is appropriate that precision measures need testing solution, adds acetonitrile-water (40:60) and make the solution solution in contrast containing 1 μ g in every 1ml; Measure contrast solution 20 μ l, injection liquid chromatography, regulate detection sensitivity, make the peak height of main constituent chromatographic peak be about the 15%-20% of full scale; Another precision measures need testing solution 20 μ l, injection liquid chromatography, and record chromatogram is to 3.5 times of main constituent peak retention time.In the chromatogram of need testing solution, single impurity peak area calculates with Self-control method, calculates maximum single impurity peak area and total assorted peak area respectively.
Liprevil dissolubility of calcium measures:
Get pharmaceutical composition of the present invention (capsule one or tablet a slice), according to dissolution method (Chinese Pharmacopoeia version in 2010 two annex XC second methods), with water 900ml for dissolution medium, rotating speed is 50 turns per minute, operate in accordance with the law, through 30 minutes time, get solution 5ml, filter, get subsequent filtrate as need testing solution; Separately get Pitavastatin Calcium reference substance appropriate, quantitatively dilute the solution made about containing 1 μ g in every 1ml with dissolution medium, product solution in contrast.Measure, by external standard method with the stripping quantity of the every sheet of calculated by peak area according to the method under assay item.
Beneficial effect of the present invention is, the present invention forms stable solid dispersion by hydrophilic carrier and Pitavastatin Calcium, improve the dissolution rate of Pitavastatin Calcium, improve the stability of Pitavastatin Calcium, expand the pharmaceutical carrier scope of application, preparation method of the present invention can be directly used in suitability for industrialized production.
Specific embodiment
embodiment 1
Solvent method prepares Pitavastatin Calcium solid dispersion
Take Pitavastatin Calcium 1.0g and carrier (one or more in PVPk30, PEG4000, PEG6000, F68) 5.0g respectively, first carrier is joined in 50.0mL dehydrated alcohol, be stirred to after dissolving completely, add after Pitavastatin Calcium Keep agitation 1h fully mixes, 60 DEG C of concentrating under reduced pressure removing ethanol, product is 48h in the underlying vacuum desiccator of room temperature, porphyrize, cross 80 mesh sieves, save backup.
Prepared by pharmaceutical composition: take the Pitavastatin Calcium solid dispersion being equivalent to Pitavastatin Calcium 1g, low-substituted hydroxypropyl cellulose 12.0g, hypromellose 2.0g, magnesium stearate 1.2g, by pharmaceutical industry conventional method tabletting, make 1000.
comparison example 1
Prepare Pitavastatin Calcium physical mixture
Respectively accurate took 80 mesh sieves Pitavastatin Calcium 1.0g and carrier (one or more in PVPk30, PEG4000, PEG6000, F68) 5.0g, mix in mortar with equivalent method of progressively increasing, put in exsiccator and save backup.
Prepared by pharmaceutical composition: take the Pitavastatin Calcium physical mixture being equivalent to Pitavastatin Calcium 1g, low-substituted hydroxypropyl cellulose 12.0g, hypromellose 2.0g, magnesium stearate 1.2g, by pharmaceutical industry conventional method tabletting, make 1000.
Embodiment 1 and comparative example 1 sample are investigated 6 months in accelerated test condition (40 DEG C ± 2 DEG C, RH75% ± 5%) DEG C calorstat, observes the situation of change of tablet appearance, content, dissolution and related substance.Experimental result is in table 1.
embodiment 2
Fusion method prepares Pitavastatin Calcium solid dispersion
Take Pitavastatin Calcium 1.0g and carrier (one or more in PEG4000, PEG6000, F68) 5.0g respectively, first carrier to be placed in 60 DEG C of water-baths after dissolving completely, add after Pitavastatin Calcium Keep agitation 1h fully mixes, be transferred to rapidly-20 DEG C of solidification 12h, take out, 48h in the underlying vacuum desiccator of room temperature, porphyrize, cross 80 mesh sieves, save backup.
Prepared by pharmaceutical composition: take the Pitavastatin Calcium solid dispersion being equivalent to Pitavastatin Calcium 1g, low-substituted hydroxypropyl cellulose 12.0g, hypromellose 2.0g, magnesium stearate 1.2g, by pharmaceutical industry conventional method tabletting, make 1000.
comparison example 2
Prepare Pitavastatin Calcium physical mixture
Respectively accurate took 80 mesh sieves Pitavastatin Calcium 1.0g and carrier (one or more in PEG4000, PEG6000, F68) 5.0g, mix in mortar with equivalent method of progressively increasing, put in exsiccator and save backup.
Prepared by pharmaceutical composition: take the Pitavastatin Calcium physical mixture being equivalent to Pitavastatin Calcium 1g, low-substituted hydroxypropyl cellulose 12.0g, hypromellose 2.0g, magnesium stearate 1.2g, by pharmaceutical industry conventional method tabletting, make 1000.
Embodiment 2 and comparative example 2 sample are investigated 6 months in accelerated test condition (40 DEG C ± 2 DEG C, RH75% ± 5%) DEG C calorstat, observes the situation of change of tablet appearance, content, dissolution and related substance.Experimental result is in table 1.
embodiment 3
Solvent-fusion method prepares Pitavastatin Calcium solid dispersion
Take Pitavastatin Calcium 1.0g and carrier (one or more in PEG4000, PEG6000, F68) 5.0g respectively, first Pitavastatin Calcium 20mL dehydrated alcohol is dissolved completely, carrier to be placed in 60 DEG C of water-baths after dissolving completely, to add after Pitavastatin Calcium alcoholic solution Keep agitation 1h fully mixes, 60 DEG C of concentrating under reduced pressure removing ethanol, be transferred to rapidly-20 DEG C of solidification 12h, take out, 48h in the underlying vacuum desiccator of room temperature, porphyrize, cross 80 order mesh sieves, save backup.
Prepared by pharmaceutical composition: take the Pitavastatin Calcium solid dispersion being equivalent to Pitavastatin Calcium 1g, low-substituted hydroxypropyl cellulose 12.0g, hypromellose 2.0g, magnesium stearate 1.2g, by pharmaceutical industry conventional method tabletting, make 1000.
comparison example 3
Prepare Pitavastatin Calcium physical mixture
Respectively accurate took 80 mesh sieves Pitavastatin Calcium 1.0g and carrier (one or more in PEG4000, PEG6000, F68) 5.0g, mix in mortar with equivalent method of progressively increasing, put in exsiccator and save backup.
Prepared by pharmaceutical composition: take the Pitavastatin Calcium physical mixture being equivalent to Pitavastatin Calcium 1g, low-substituted hydroxypropyl cellulose 12.0g, hypromellose 2.0g, magnesium stearate 1.2g, by pharmaceutical industry conventional method tabletting, make 1000.
Embodiment 3 and comparative example 3 sample are investigated 6 months in accelerated test condition (40 DEG C ± 2 DEG C, RH75% ± 5%) DEG C calorstat, observes the situation of change of tablet appearance, content, dissolution and related substance.Experimental result is in table 1.
Table 1 pharmaceutical composition study on the stability result
Result shows: use the tablet prepared by Pitavastatin Calcium solid dispersion, compared with the tablet prepared with routine, dissolution be improved significantly, and related substance has no remarkable growth, and stability is better.
Claims (9)
1. the pharmaceutical composition containing Pitavastatin Calcium, is characterized in that: described Pitavastatin Calcium is the solid dispersion of Pitavastatin Calcium.
2. the pharmaceutical composition containing Pitavastatin Calcium according to claim 1, is characterized in that: by weight percentage, filler, the disintegrating agent of 0-40%, the binding agent of 0-20%, the lubricant of 0-10% of described compositions also containing 0-90%;
Described filler is one or more in calcium phosphate, lactose, mannitol, microcrystalline Cellulose, starch, sorbitol;
Described disintegrating agent is one or more in low-substituted hydroxypropyl cellulose, polyvinylpyrrolidone, starch, cross-linking sodium carboxymethyl cellulose, polyvinylpolypyrrolidone;
Described lubricant is one or more in magnesium stearate, stearic acid, Pulvis Talci, silicon dioxide;
Described binding agent is one or more in the alcoholic solution of hyprolose, hypromellose, polyvinylpyrrolidone, starch slurry, water, various concentration.
3. the pharmaceutical composition containing Pitavastatin Calcium according to claim 2, it is characterized in that: by weight percentage, described compositions is made up of the magnesium stearate of the lactose of the solid dispersion of the Pitavastatin Calcium of 1-100%, 0-90%, the low-substituted hydroxypropyl cellulose of 0-40%, the hypromellose of 0-20% and 0-10%.
4. according to any one of claim 1-3 containing the pharmaceutical composition of Pitavastatin Calcium, it is characterized in that: the carrier of described solid dispersion is one or more in PEG4000, PEG6000, PLURONICS F87, pvpk30.
5. the pharmaceutical composition containing Pitavastatin Calcium according to claim 4, is characterized in that: the weight of the carrier of described solid dispersion is 5 times of Pitavastatin Calcium weight.
6. prepare a method for the pharmaceutical composition containing Pitavastatin Calcium as described in any one of claim 1-3, it is characterized in that, described preparation method comprises following steps:
The first step: the solid dispersion preparing Pitavastatin Calcium;
Second step: the solid dispersion accurately taking the Pitavastatin Calcium containing recipe quantity Pitavastatin Calcium, mixes with other pharmaceutical carrier, prepares oral solid formulation by preparation industry conventional method.
7. preparation according to claim 6 contains the method for the compositions of Pitavastatin Calcium, it is characterized in that, the described method preparing the solid dispersion of Pitavastatin Calcium is solvent method, and concrete steps are as follows: be added to by carrier in dehydrated alcohol, be stirred to and dissolve completely, add after Pitavastatin Calcium is stirred to fully mixing, removing ethanol, dry, porphyrize, sieve, preserve.
8. preparation according to claim 6 contains the method for the compositions of Pitavastatin Calcium, it is characterized in that, the described method preparing the solid dispersion of Pitavastatin Calcium is fusion method, concrete steps are as follows: by complete for carrier melting, add after Pitavastatin Calcium is stirred to fully mixing ,-20 DEG C of low-temperature settings, dry, porphyrize, sieves, and preserves.
9. preparation according to claim 6 contains the method for the compositions of Pitavastatin Calcium, it is characterized in that, the described method preparing the solid dispersion of Pitavastatin Calcium is solvent-fusion method, and concrete steps are as follows: by complete for carrier melting, adds after Pitavastatin Calcium alcoholic solution is stirred to fully mixing, removing ethanol,-20 DEG C of low-temperature settings, dry, porphyrize, sieve, preserve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510655979.0A CN105125545A (en) | 2015-10-13 | 2015-10-13 | Medicine composition containing pitavastatin calcium and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510655979.0A CN105125545A (en) | 2015-10-13 | 2015-10-13 | Medicine composition containing pitavastatin calcium and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105125545A true CN105125545A (en) | 2015-12-09 |
Family
ID=54711369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510655979.0A Withdrawn CN105125545A (en) | 2015-10-13 | 2015-10-13 | Medicine composition containing pitavastatin calcium and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105125545A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343008A (en) * | 2015-12-15 | 2016-02-24 | 青岛华之草医药科技有限公司 | Pitavastatin calcium composition |
| CN105412017A (en) * | 2015-12-15 | 2016-03-23 | 青岛华之草医药科技有限公司 | Method for preparing pitavastatin calcium composition |
| CN107854443A (en) * | 2017-11-28 | 2018-03-30 | 徐州生物工程职业技术学院 | A kind of Pitavastatin calcium dispersible tablet and preparation method thereof |
| CN108567743A (en) * | 2017-03-14 | 2018-09-25 | 上海现代药物制剂工程研究中心有限公司 | Statins solid dispersions, preparation and preparation method thereof |
| CN111743869A (en) * | 2019-03-29 | 2020-10-09 | 南京济群医药科技股份有限公司 | Pitavastatin calcium tablet and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709253A (en) * | 2005-06-08 | 2005-12-21 | 重庆医药工业研究院有限责任公司 | Stable medicinal composition containing pitavastatin |
| KR20110092804A (en) * | 2010-02-10 | 2011-08-18 | 고원팜 주식회사 | Pharmaceutical composition containing pitavastatin calcium salt |
| CN102258459A (en) * | 2011-08-17 | 2011-11-30 | 南京正宽医药科技有限公司 | Rosuvastatin calcium oral solid preparation and applications thereof |
-
2015
- 2015-10-13 CN CN201510655979.0A patent/CN105125545A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709253A (en) * | 2005-06-08 | 2005-12-21 | 重庆医药工业研究院有限责任公司 | Stable medicinal composition containing pitavastatin |
| KR20110092804A (en) * | 2010-02-10 | 2011-08-18 | 고원팜 주식회사 | Pharmaceutical composition containing pitavastatin calcium salt |
| CN102258459A (en) * | 2011-08-17 | 2011-11-30 | 南京正宽医药科技有限公司 | Rosuvastatin calcium oral solid preparation and applications thereof |
Non-Patent Citations (1)
| Title |
|---|
| 彭霞: "辛伐他汀固体分散体的研究", 《中国优秀硕士学位论文全文数据库工程科技Ⅰ辑》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343008A (en) * | 2015-12-15 | 2016-02-24 | 青岛华之草医药科技有限公司 | Pitavastatin calcium composition |
| CN105412017A (en) * | 2015-12-15 | 2016-03-23 | 青岛华之草医药科技有限公司 | Method for preparing pitavastatin calcium composition |
| CN108567743A (en) * | 2017-03-14 | 2018-09-25 | 上海现代药物制剂工程研究中心有限公司 | Statins solid dispersions, preparation and preparation method thereof |
| CN107854443A (en) * | 2017-11-28 | 2018-03-30 | 徐州生物工程职业技术学院 | A kind of Pitavastatin calcium dispersible tablet and preparation method thereof |
| CN111743869A (en) * | 2019-03-29 | 2020-10-09 | 南京济群医药科技股份有限公司 | Pitavastatin calcium tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5775464B2 (en) | Delayed release oral dosage composition containing amorphous CDDO-ME | |
| CN105125545A (en) | Medicine composition containing pitavastatin calcium and preparing method thereof | |
| EP3981399A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| CN101816639B (en) | Tablets of mosapride citrate and preparation method thereof | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN110037994A (en) | A kind of brufen quick-release and slow-release double-layer tablets and preparation method thereof | |
| CN103127025A (en) | Racemic 2-(alpha-hydroxyl amyl) benzoate tablets and preparation method thereof | |
| CN114288257A (en) | Fluvoxamine maleate tablet and preparation method thereof | |
| CN103142529B (en) | Indapamide sustained-release drug composite and preparation method thereof | |
| EP2050436A1 (en) | Pharmaceutical composition containing dutasteride | |
| CN104814923A (en) | Tamsulosin Hydrochloride sustained-release preparation, preparation method and applications thereof | |
| CN104586804A (en) | Preparation method for letrozole tablets with good stability | |
| CN103860502B (en) | A kind of tablet containing moxonidine hydrochloride and preparation method thereof | |
| CN103860511B (en) | A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof | |
| CN103356495B (en) | A kind of Letrozole tablet and preparation method thereof | |
| CN102293759A (en) | Dextral ibuprofen sustained release tablet preparation and preparation method thereof | |
| CN105878200A (en) | Trimetazidine hydrochloride sustained release tablets and preparation method thereof | |
| CN105343008A (en) | Pitavastatin calcium composition | |
| JP2016037463A (en) | Pharmaceutical composition containing voriconazole | |
| CN105412017A (en) | Method for preparing pitavastatin calcium composition | |
| CN103405394A (en) | Metoprolol tartrate sustained release tablet and preparation method thereof | |
| CN103989680B (en) | A kind of pharmaceutical composition containing Pitavastatin Calcium | |
| CN103845332A (en) | Medicinal dasatinib composition and preparation method thereof | |
| CN109381431B (en) | Huperzine A sustained-release pellet and preparation method thereof | |
| CN110917170A (en) | Candesartan cilexetil-containing capsule preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151209 |